MannKind beats Q4 expectations, shares target raised to $6.50 at Oppenheimer

Published on 28 Feb 2024 on Investing.com

On Wednesday, Oppenheimer maintained its Outperform rating on MannKind (NASDAQ: MNKD ) Corporation...

Read the rest of the article

Start tracking your investments with Statfolio

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be...

Simply Wall St. · via Yahoo Finance 3 Feb 2025

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we ...

Insider Monkey · via Yahoo Finance 6 Jan 2025

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developin...

Insider Monkey · via Yahoo Finance 21 Sep 2024

Key Insights MannKind will host its Annual General Meeting on 15th of MayCEO Michael Castagna's t...

Simply Wall St. via Yahoo Finance 9 May 2024

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript May 8, 2024 MannKind Corporat...

Insider Monkey via Yahoo Finance 9 May 2024

Key Insights Given the large stake in the stock by institutions, MannKind's stock price might be ...

Simply Wall St. via Yahoo Finance 2 Apr 2024

MannKind to present new inhaled insulin study data at ATTD

Investing.com 5 Mar 2024

Celebrations may be in order for MannKind Corporation (NASDAQ:MNKD) shareholders, with the analys...

Simply Wall St. via Yahoo Finance 3 Mar 2024

MannKind Corporation (NASDAQ:MNKD) Q4 2023 Earnings Call Transcript February 27, 2024 MannKind Co...

Insider Monkey via Yahoo Finance 29 Feb 2024

Image source: The Motley Fool. MannKind (NASDAQ: MNKD)Q4 2023 Earnings CallFeb 27, 2024, 5:00 p.m...

Motley Fool via Yahoo Finance 28 Feb 2024